Lv1
78 积分 2025-01-16 加入
Factors influencing the initial glycemic efficacy of dorzagliatin, a novel glucokinase activator, in type 2 diabetes
1天前
已完结
Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial
2个月前
已完结
FRI-313-A novel farnesoid X receptor agonist, TERN-101, reduces liver steatosis, inflammation, ballooning and fibrosis in a murine model of non-alcoholic steatohepatitis
2个月前
已完结
Development of Cilofexor, an Intestinally-Biased Farnesoid X Receptor Agonist, for the Treatment of Fatty Liver Disease
2个月前
已完结
Disentangling Organ‐Specific Roles of Farnesoid X Receptor in Bile Acid and Glucolipid Metabolism
2个月前
已完结
Tropifexor-Mediated Abrogation of Steatohepatitis and Fibrosis Is Associated With the Antioxidative Gene Expression Profile in Rodents
2个月前
已完结
Glucagon, GLP-1 and Thermogenesis
2个月前
已完结
Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells
2个月前
已完结
Farnesoid X receptor: An important factor in blood glucose regulation
2个月前
已完结
Insulin resistance and adipose tissue interactions as the cornerstone of metabolic (dysfunction)-associated fatty liver disease pathogenesis
2个月前
已完结